Nymox Pharmaceutical Corp (NASDAQ:NYMX)

CAPS Rating: 1 out of 5

A biopharmaceutical company with three proprietary products on the market and a R&D of drug & diagnostic products in development for the treatment of enlarged prostate, Alzheimer's disease contamination of food and drink products and bacterial infections.

Results 1 - 16 of 16

Recs

1
Member Avatar zzlangerhans (99.85) Submitted: 11/19/2014 1:35:02 AM : Underperform Start Price: $0.55 NYMX Score: +15.86

What's the point of coming back and giving Nymox one last kick in the teeth? I've already made my point about the futility of investing in this pathetic scam several times, and I was vindicated when the company finally reported failure of the phase III trials of NX-1207 for BPH earlier this month. Despite being absolutely right about the outcome of the trials, my put options expired worthless in August as Nymox management sat on the results of the trials, which they almost certainly had in hand by the end of June. Of course, that didn't stop secretive CEO Paul Averback from selling large chunks of Nymox stock over 6 as recently as October. Is there such thing as a class action suit for options holders?

The reason I'm back is to drive home a point about trading biopharma stocks without genuine due diligence, which involves a hefty dose of skepticism. People tend to remember the huge winners like Pharmacyclics and Regeneron and forget about the multitudes of failures, many of which were never serious developmental ventures. The sector is filled with parasites who leech off the good faith engendered by the success stories. Sometimes these parasites are hard to identify, and sometimes they are easy. They don't come much easier than Nymox. The number of red flags here was epic - the company's refusal to divulge the composition or mechanism of NX-1207, the mysterious origin of their funding from a shell corporation in Panama, their ridiculously low cash utilization despite their claim to be conducting several late stage clinical trials, the minimalist nature of their quarterly PR's, and of course the obvious fact that they were sitting on data many months after the conclusion of phase III trials. Nevertheless, Nymox stock improbably maintained a share price over 5 as those months slipped by and it became even more obvious to objective observers that the trials had failed.

If you were long Nymox when they finally released the negative data and the stock dropped 80%, despite all of these red flags and the clear expert commentary predicting failure, you need to do one of two things:

1. Sell all your individual equities, buy SPY, and forget the password to your brokerage account. You are wasting time and money attempting to trade stocks. Save your time and energy for fantasy football and the Drudge Report.

2. Wipe your slate clean and start over. Admit you know nothing. Get off the YMB and Stocktwits. Learn the red flags, and learn who the smart skeptics are on the web and Twitter. Let others convince you not to buy a stock, but never let anyone else convince you to buy a stock. Develop your own process for deciding what stocks are worth buying. If your performance fails to improve, go to choice 1.

By the way, retail traders weren't the only ones caught in the Nymox blow-up. A list of supposed professionals who owned a piece of the scam can be found here http://whalewisdom.com/stock/nymx . Mercifully it's a short list but it might be worth a quick look. If you have any money in the hands of any organization that owned more than a nominal amount of Nymox stock when it dumped, you might want to rethink that association.

Recs

0
Member Avatar TooTall100 (< 20) Submitted: 8/11/2014 8:38:56 PM : Outperform Start Price: $5.58 NYMX Score: -98.25

Phase 3 clinical trials are complete on an injection treatment for BPH, an illness affecting most men over age 50. The treatment does not require taking a med every day, can be performed outpatient in minutes by a urologist. The effects are measurable within a few weeks, so it seems likely they will be able to apply for approval soon, but I am not sure how long it will be.

Recs

0
Member Avatar pchop123 (80.37) Submitted: 8/7/2014 11:28:28 AM : Underperform Start Price: $5.47 NYMX Score: +99.05

in difficulty now

Recs

0
Member Avatar r3r2r1 (< 20) Submitted: 11/1/2013 12:23:23 PM : Outperform Start Price: $7.05 NYMX Score: -110.98

So far their N prostate drug has outstanding results as it works thru stage 3 tests. This could be a game changer for men!

Recs

0
Member Avatar SaiyanBroker (42.51) Submitted: 3/1/2013 5:22:10 PM : Outperform Start Price: $5.33 NYMX Score: -126.92

How do I say this placidly? I'm expecting the micro-cap pharmy's price to erect. Along with a series of other drugs, the flagship of the corporation, Nx1207, a "proprietary" treatment for BPH, is not allergenic with intraprostatic injections, according to Nymox, "positive immunogenicity testing of NX-1207 is an important step in the Company's drug development program." I worry that there could be political ramifications of the drug post release as it will crush tabular competition. Possible measures to even the playing field for alternatives could be an imposed price floor. Otherwise this one's gonna literally rock the baby boat. It's a spit ball.

http://www.youtube.com/watch?v=dndAXxqJbc0

http://www.4-traders.com/NYMOX-PHARMACEUTICAL-CORP-10305/news/Nymox-Pharmaceutical-Corporation-Nymox-Announces-Positive-Immunogenicity-Results-for-NX-1207-BPH-P-16247327/

I'm confident enough to actually risk this one with real dough. Got ~$500 in at $5.22/share betting this one sees a pretty feline. *Growl*

Recs

0
Member Avatar vis1798 (< 20) Submitted: 9/8/2012 6:25:13 AM : Outperform Start Price: $5.95 NYMX Score: -135.92

New approved drug for BPH - This thing is going to take off.

Recs

1
Member Avatar mshakin1 (< 20) Submitted: 5/27/2010 2:50:11 PM : Outperform Start Price: $4.71 NYMX Score: -177.77

The NYMOX drug for BPH, NX1207, is head and shoulders above all the existing drugs for this ailment, which affects tens of millions of middle age and elderly men. Not only is NX1207 so much more effective than Flomax and Avodart is decreasing BPH, but it also doesn't have the sexual side effects. And instead of taking hose drugs every day forever, NX1207 is an injection administered in a urologist's office only once every several years.
This drug has tremendous potential. To become a blockbuster, it doesn't have to be recognized as a great drug by consumers, but rather by urologists, who will be well aware of how much better it is than the alternative oral drugs.

Recs

0
Member Avatar shupenobama (< 20) Submitted: 11/27/2009 7:54:04 PM : Outperform Start Price: $4.30 NYMX Score: -177.71

will explode when BPH treatment nears approval

Recs

0
Member Avatar mepedrou (< 20) Submitted: 1/8/2009 2:28:58 PM : Outperform Start Price: $3.55 NYMX Score: -219.71

nx 1207 drug a guaranteed winner

Recs

0
Member Avatar GershwinStephen (< 20) Submitted: 1/30/2008 5:33:55 PM : Outperform Start Price: $5.07 NYMX Score: -152.07

acquisiton,

Recs

2
Member Avatar NeroSagetrade (89.56) Submitted: 10/11/2007 6:53:50 PM : Underperform Start Price: $6.25 NYMX Score: +131.66

There are far too many of these types of pharmaceutical companies out there...plenty of promise, huge valuation and failure to deliver. Nymox currently has one...yes..only one drug currently in late stage trials to treat enlarging prostates. The company has managed just 450k in sales for the entire year yet is valued at over 183 million dollars. Losses are increasing, and based on my estimates, they dont even have enough cash to get out of Q1 2008! Over 400 times price to sales, 58 times book, and increasing losses..where's the buy button?!! If you look historically at the long-term chart, this falls mercilessly for 2-3 months after every large rise.

Nero

Sagetrade

Recs

1
Member Avatar Voyt608 (< 20) Submitted: 4/12/2007 9:07:23 AM : Outperform Start Price: $5.61 NYMX Score: -143.52

Non estrogenic treatment for benign proatatic hyperplasia with proven efficacy ih reducing symptoms such as frepuent voiding, urgency, nocturia, dripping etc. No significant side effects and a 30% reduction in prostate size in late trials. Tremendous market potential.

Recs

2
Member Avatar NetscribeHealthC (64.17) Submitted: 3/23/2007 9:26:46 AM : Underperform Start Price: $5.95 NYMX Score: +144.48

Nymox Pharmaceutical Corporation (Nymox) is a biopharmaceutical company that owns and operates business through two subsidiaries: Nymox Corporation, a wholly owned subsidiary and Serex, Inc., a majority owned subsidiary. The company has three products in its portfolio; AlzheimAlert meant to measure the level of a brain protein, NicAlert to determine smoking status and TobacAlert determination of a person’s level of exposure to tobacco products including second hand smoke.

The company is pursuing research and development pipeline of drug and diagnostic products in development for the treatment of such conditions and diseases as enlarged prostate (benign prostatic hyperplasia (BPH)), Alzheimer's disease (AD), E. coli O157:H7 contamination of food and drink products, and bacterial infections and for the diagnosis of AD and other indications.

Nymox’s financial statements indicate that it is still very much in its development phase. For the fiscal 2006 its revenues were mere $0.44 million whereas it reported net loss of $4.89 million which was 63% more than the previous year.

The driver for this stock would be its Phase II product candidate NX-1207 which is meant to treat BPH. The stocked reacted positively on the recent announcement of positive test data.

The company’s valuation looks expensive especially if one takes into account its $ 44 million deficit and that it is going to take few years for it to generate positive free cash flows. Thus in today’s environment where risk aversion is the norm this stock doesn’t make the grade. Hence its better to be prudent while thinking of investing in the stock.

Recs

0
Member Avatar fiona53 (< 20) Submitted: 2/18/2007 4:03:24 AM : Outperform Start Price: $5.70 NYMX Score: -142.35

very interesting pipeline

Recs

0
Member Avatar bdylan (< 20) Submitted: 2/8/2007 9:26:10 PM : Outperform Start Price: $5.25 NYMX Score: -142.16

Nymox has intellectual patented technology worldwide with statin gene marker for alzheimers disease.
Their drug for shrinking prostate gland that has enlarged has no known high risk side effects. Their research on eliminating the ecoli bacteria in food is moving forward . I bleive this company is positioned for solid growth thru revenues and earnings generated by these proprietory techniques and the royalties generated by these products :leased: to other major pharmaceutical companies should enhance earnings and price..

Recs

0
Member Avatar jeromeluther (< 20) Submitted: 2/5/2007 11:04:12 PM : Outperform Start Price: $4.70 NYMX Score: -141.20

New prostrate drug could be big. Also has very strong Alzheimers drug

Results 1 - 16 of 16

Featured Broker Partners


Advertisement